Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Treatment of JIA (2 of 2)
Anti-inflammatory drugs alone are often inadequate to relieve symptoms and limit progression of disease.
DMARDs are now in common use for JIA, and several have been approved by the U.S. Food and Drug Administration for this indication. DMARDs inhibit the immune cells and mechanisms underlying the symptoms of rheumatic disease. There are two classes of DMARDs: biologic and non-biologic.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.